The rationale for blending these two peptides stems from their non-overlapping receptor targets and complementary metabolic effects: Amylin Pathway (Cagrilintide): Targets amylin receptors in the brainstem Creates meal-specific satiety signals Slows gastric emptying through distinct mechanisms Reduces meal size and eating frequency Triple Agonist Pathway (Retatrutide): Activates GIP, GLP-1, and glucagon receptors Enhances insulin secretion and glucose metabolism Increases energy expenditure through glucagon effects Provides broader metabolic regulation When combined, these pathways could theoretically provide additive or synergistic effects on weight management and metabolic function
For mTYR, H60, H84 and H93 chelate CuA, while H258, H262 and H295 chelate CuB
Whether this meaningfully reduces probiotic viability in GLP-1 users has not been directly studied
Semaglutide helps the body respond better to food intake and supports more stable glucose control through the day
Understanding these variables helps set realistic expectations and optimize treatment outcomes
Editorial Advisory Board Member, Harvard Health Publishing Q